The mechanisms of persistence to ciprofloxacin in nine sets of Pseudomonas aeruginosa strains isolated during ciprofloxacin therapy of chronic lung infections in cystic fibrosis patients were studied. Low to moderate levels of ciprofloxacin resistance developed in each case. Each set of pretherapy ciprofloxacin-susceptible, during-therapy ciprofloxacin-resistant, and posttherapy ciprofloxacin-susceptible isolates were shown to be genotypically related by using a radiolabeled epidemiological gene probe. All ciprofloxacin-resistant isolates were found to have altered susceptibilities to both nalidixic acid and various chemically unrelated antibiotics. Analysis of possible resistance mechanisms showed that the strains had altered outer membrane protein or lipopolysaccharide profiles. Complementation of possible DNA gyrase mutations with a plasmid-borne, wild-type Escherichia coli gyrA gene indicated that altered DNA gyrase was at least partly responsible for ciprofloxacin resistance in all strains tested. Attempts to generate ciprofloxacin-susceptible revertants in vitro showed that in some strains reversion was rapid in the absence of ciprofloxacin, while in other strains it was not possible to generate revertants. These data indicate that persistence of Pseudomonas aeruginosa to ciprofloxacin involves changes in DNA gyrase and is associated with pleiotropic changes in outer membrane proteins and lipopolysaccharide.
Fluoroquinolones are synthetic antimicrobial agents with potent activity against gram-negative and gram-positive bacteria. Ciprofloxacin is one of the most active drugs against Pseudomonas aeruginosa, and its use in the treatment of lung infections in patients with cystic fibrosis is increasing (2, 24, 43) . Patients generally show improvements in pulmonary function tests and X-ray scores, in the absence of complete eradication of P. aeruginosa from the sputum (4) .
Fluoroquinolones interfere with the activity of DNA gyrase, an essential bacterial type II DNA topoisomerase (14, 44) . There have been reports of the resistance of P. aeruginosa to ciprofloxacin occurring during drug therapy (11, 12) , and there are also worrying epidemiological reports of increasing frequencies of ciprofloxacin-resistant P. aeruginosa isolates emerging concomitantly with increasing use of the drug (8, 26) . In vitro studies of quinolone resistance development in P. aeruginosa PAO have identified a number of loci in which mutations can produce resistance. Alterations in DNA gyrase (gyrA [cfxA nfxA nalA]) or cell permeability (nfxB cfxB nalB nfxC) may result in decreased susceptibility to ciprofloxacin (38) , norfloxacin (13, 20) , and nalidixic acid (36) .
Detailed investigations into the mechanisms of fluoroquinolone resistance that occur in clinical isolates are rare.
Often, a susceptible parent isolate in unavailable, making precise study of resistance-producing changes difficult. A number of reports, however, have shown changes in P. aeruginosa DNA gyrase (6, 25, 30, 37, 48) , changes in membrane structure and function (6, 7, 25, 30, 35) , or both to be linked to fluoroquinolone resistance. Some of these studies have shown resistance development to be due to changes in a particular strain rather than reinfection with an already resistant strain (6, 25, 30, 34, 35) . * Corresponding author.
In the case of P. aeruginosa infections in the lungs of cystic fibrosis patients, ciprofloxacin resistance development appears to be a persistence phenomenon (6) . Persistence is most likely to develop when the host defences are impaired, drug entry or availability at the infection site is poor, or antimicrobial action is antagonized or destroyed. Persistence is often associated with low to moderate resistance levels, lack of stability, and loss or reduction of a gene function (4, 5) . In a previous study (6) , a persistent resistant strain of P. aeruginosa isolated during ciprofloxacin therapy of a lung infection in a cystic fibrosis patient was found to have altered DNA gyrase (shown by an alteration in sensitivity of in vitro DNA synthesis inhibition) and altered outer membrane proteins and lipopolysaccharide (LPS). The aim of this study was to examine persistence mechanisms in a greater number of ciprofloxacin therapy episodes of P. aeruginosa lung infections in patients with cystic fibrosis.
MATERIALS AND METHODS
Media. The following media were used in this study:
Mueller-Hinton agar (MHA) and broth (MHB) and MacConkey agar (GIBCO Diagnostics, Madison, Wis.) and tryptone soy agar and broth, brain heart infusion agar and broth, and Luria agar and broth (Difco Laboratories, De (27) . Gels were stained with 0.25% Coomassie blue R.
LPS extraction and analysis. LPS was isolated as described previously (6) and was silver stained by the method of Hitchcock and Brown (21) .
Accumulation of ciprofloxacin. Accumulation of ciprofloxacin by P. aeruginosa strains was measured as described previously (6 CAT analysis. Cells were grown to the stationary phase in tryptone soy broth, washed in 0.1 M Tris hydrochloride (pH 7.8) containing 1 mM MgCl2, and concentrated 50-fold in the same buffer. Cells were lysed by sonication at 0°C and centrifuged to remove cell debris. The chloramphenicol acetyltransferase (CAT) activities of the supernatants were measured by the method of Shaw and Brodsky (41) . P. aeruginosa RM265 harboring the CAT-producing plasmid pKT210 was used as a positive control.
Complementation of the chromosomal gyrA gene with a plasmid-borne, wild-type Escherichia coli gyrA gene. E. coli S17-1 (Pro-Res-Mod' Tpr Smr) (42) containing either the broad-host-range cloning vector pLA2917 (1) or the plasmid pNJR3-2 (37) containing the wild-type E. coli gyrA gene (45) was obtained from N. J. Robillard, Miles Inc., West Haven, Conn.
The plasmid pNJR3-2 was used to complement possible quinolone-resistant, chromosomally located gyrA genes in the ciprofloxacin-resistant isolates. The plasmid was introduced into the strains either by electroporation (9) with plasmid purified by standard procedures or by matings described previously (37) , except that brain heart infusion agar and broth were used and the concentration of tetracycline used to select for P. aeruginosa transconjugants was 400 ,ug/ml. Complementation of DNA gyrase was tested by standard agar dilution susceptibility testing methods by using MHA containing 100 ,ug of tetracycline per ml. Plasmids were shown to be stably maintained in each host strain under positive selection pressure for tetracycline resistance.
Analysis of native plasmids. Sets P, U, W, and Y were examined for the presence of large native plasmids by the methods of Hansen and Olsen (19) . Plasmid samples were electrophoresed through 0.7% agarose gels by using TAE 
RESULTS
Assessment of patient symptoms. All treatment episodes resulted in a significant improvement in symptoms. Pulmonary function tests, chest X-ray scores, and clinical scores improved when pretherapy assessment was compared with posttherapy follow-up (data not shown).
Bacteriological analysis of expectorated sputum. Bacteriological analyses of sputum samples revealed that each patient was colonized with up to four colonial morphotypes of P. aeruginosa. Quantitative analysis showed a decrease in the total numbers of P. aeruginosa organisms concomitant with ciprofloxacin therapy. Figure 1 shows data for one patient during two separate ciprofloxacin therapy periods, each lasting 14 days and being separated by 4 months. The total numbers of viable P. aeruginosa organisms declined during therapy, but they were never completely eradicated. As rapidly as 1 day following the cessation of therapy, the total numbers of viable P. aeruginosa returned to pretherapy levels. Changes in the growth inhibition zone produced by a 5-,ug ciprofloxacin disk were recorded and are also shown in Fig. 1 (group B); and sets R, S, and X were grouped with set U (group C). In addition to the increase in the MICs of quinolones, each group showed the following characteristics. Group A showed decreased susceptibility to gentamicin, carbenicillin, and cefotaxime; group B showed decreased susceptibility to tetracycline; group C became less susceptible to chloramphenicol but hypersusceptible to carbenicillin and cefotaxime; and group D became hypersusceptible to gentamicin, carbenicillin, cefotaxime, and imipenem.
Generation of in vitro revertants of therapy isolates. Ciprofloxacin-resistant therapy isolates were subcultured onto antimicrobial agent-free MHA for up to 40 passages. Antimicrobial agent disk inhibition zone sizes were measured daily for a number of agents. In addition, MICs of the antibiotics listed in Table 1 were determined after the final passage. In contrast to the posttherapy in vivo isolate, full reversion of ciprofloxacin susceptibility to pretherapy levels could only be generated in vitro in sets U and X. Both of these sets of strains showed full reversion to pretherapy susceptibility for both quinolone and nonquinolone antimicrobial agents. In contrast, for sets P, Q, S, and Y, the MICs of quinolone or nonquinolone agents were unchanged. Other sets (sets R, V, and W) showed a partial in vitro reversion to ciprofloxacin susceptibility. MIC data for the in vitro-generated revertant of set U are given in Table 1 .
By daily monitoring the disk zone size changes, it was possible to determine how quickly reversion to quinolone susceptibility occurred and also whether changes in quinolone susceptibility were accompanied by changes in susceptibility to nonquinolone antibiotics. The zone size changes for the set U therapy isolate are shown in Fig. 2 . In agreement with the MIC data for the in vitro revertants, the zone sizes of set U for gentamicin, piperacillin, and tetracycline did not change (data not shown). Figure 2 shows that reversion to ciprofloxacin and nalidixic acid susceptibility occurred after 4 to 7 subcultures and appeared to be at least a two-step process. For set V therapy isolate, partial reversion to ciprofloxacin and nalidixic acid susceptibility was accompanied by reversion to tetracycline susceptibility (data not shown). Data for other sets of revertants were also in agreement with MIC data. P-Lactamase analysis. Basal P-lactamase production was examined by monitoring nitrocefin hydrolysis by whole cells. Sets W and U produced insignificant amounts of P-lactamase, while sets P and Y produced 1-lactamase and were examined in more detail.
Analysis of ,-lactamase production by sonicated extracts of logarithmic-phase cultures of pre-, during-, and posttherapy isolates of set Y showed that equal quantities of enzyme were produced by each isolate. In set P, 3-lactamase production of the pre-, during-, and posttherapy isolates were 0.10, 25.05, and 1.00 ,umol of nitrocefin hydrolyzed per min/mg of protein, respectively. The 250-fold increase in enzyme production in the therapy strain compared with that in the pretherapy isolate is the likely cause of the large increases in MICs of P-lactam antibiotics seen with this strain. 1-lactamase production in the posttherapy isolate was increased 10-fold compared with that in the pretherapy strain; however, this increase did not correlate with altered MICs of 3-lactams, which were almost identical in pre-and posttherapy strains.
CAT. CAT production in sonicated extracts of pre-, during-, and posttherapy isolates of sets P, U, X, W, and Y was determined. It was found that all strains tested were negative for CAT compared with a positive control P. aeruginosa strain containing a CAT-producing plasmid-borne gene.
Analysis of outer membrane proteins and LPS. Outer membrane protein profiles of sets P, W, U, and Y are shown in Fig. 3 . Also included in Fig. 3B is the profile of the in vitro-generated, ciprofloxacin-susceptible revertant of the therapy strain of set U. Numerous alterations in the relative quantities of individual protein bands can be seen in each set of profiles. The major changes are summarized in Table 2 . In each set (with the exception of one high-molecular-weight band in set W), the posttherapy isolate showed full reversion of the changes in bands back to the pretherapy pattern. In addition, the in vitro-generated ciprofloxacin-susceptible revertant of set U showed reversion of protein banding pattern changes to the pretherapy pattern. LPS profiles showed that all isolates in sets U and W had rough LPS, with no exception of set Y. The accumulation kinetics of pre-, during-, and posttherapy strains are shown in Fig. 5 . Accumulation of drug by the therapy strain was approximately 50% less than that of the pre-, and posttherapy strains after 25 min. In addition, in contrast to pre-, and posttherapy strains, no further accumulation of drug by the therapy strain was detected after the initial 2 min of the assay.
Complementation of DNA gyrase. In E. coli and P. aeruginosa DNA gyrase mutants, it has been shown that, phenotypically, quinolone susceptibility is dominant over resistance (18, 31, 37, 48) . We attempted to exploit this fact by complementing possible DNA gyrase mutations in our therapy isolates with a plasmid-borne, quinolone-susceptible E. coli gyrA clone. Transformation or matings of pretherapy strains were successful in sets U and W. In set P, only the therapy strain could be transformed or mated successfully. Transformation or matings were unsuccessful with set Y.
Complementation (i.e., some reversion to ciprofloxacin susceptibility) was seen in therapy isolates of sets P, U, and W. MIC data are given in Table 3 . As control experiments, pretherapy isolates were also transformed and screened for altered quinolone susceptibility. As an additional control, all strains were transformed with the vector plasmid only. No change in ciprofloxacin susceptibility was found in pretherapy strains or in any of the strains that were transformed only with the vector plasmid. Full complementation was seen in set P, with the MIC of ciprofloxacin reverting to a twofold greater susceptibility than that for the parent strain. This result may indicate that the pretherapy strain already has a gyrase mutation that causes low-level resistance to ciprofloxacin. Unfortunately, because of the failure of successful introduction of the wild-type E. coli gyrA gene into the pretherapy isolate of set P, this result is unknown; however, the relatively high MIC of ciprofloxacin (0.5 ,ug/ml) for the pretherapy strain may indicate that a gyrase mutation was present prior to therapy. Partial complementation was seen in sets U and W, indicating that additional, non-DNA gyrase alterations contribute to the quinolone resistance in these strains.
Analysis of native plasmids. Some strains were shown to harbor high-molecular-weight plasmids; however, the presence or absence of these could not be correlated in any way with changes in antimicrobial agent susceptibility (data not shown).
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DISCUSSION
In all the treatment episodes studied, general clinical improvement was seen, despite the persistence of P. aeruginosa. In no case was P. aeruginosa completely eliminated from the sputum; however, the total numbers of bacteria isolated were significantly reduced during most therapy episodes. Failure to eradicate colonization may be due in part to the special conditions present in the cystic fibrosis lung, causing decreased activity of ciprofloxacin, despite apparently effective concentrations of drug. In addition, the large numbers of slow-growing P. aeruginosa cells may further reduce drug effectiveness and provide adequate conditions for the selection of resistance phenotypes (4). It seems likely that the persistent strains with decreased ciprofloxacin susceptibility were responsible for failure to eradicate P. aeruginosa. Symptomatic relief in the absence of eradication of bacteria may be due, in part, to the effects of ciprofloxacin on pathogenic determinants of P. aeruginosa, such as toxins (16) .
The typical pattern of persistence (return to drug susceptibility posttherapy) was seen in all sets of isolates and was found to occur as rapidly as 1 day posttherapy. We attempted to duplicate this phenomenon in vitro by serial passage on drug-free agar. In four of nine isolates, it was not possible to generate such ciprofloxacin-susceptible revertants. The other five strains showed at least partial reversion after approximately 5 to 10 subcultures; however, in only two cases (sets U and X) could in vitro revertants be generated for which their quinolone susceptibilities matched those of the posttherapy isolates. This division of reverters and nonreverters may predict how reversion occurs in vivo. In reverting strains, ciprofloxacin resistance mutations may be unstable, and removal of selective pressure on the cessation of ciprofloxacin therapy may select for susceptible revertants. In nonreverting strains, resistance mutations may be stable and reversion may occur because of the outgrowth of strains with slow-growing phenotypes with faster-growing, drug-susceptible strains, which, presumably, were not totally eradicated from the lung during therapy. It was shown experimentally in this study that some ciprofloxacin-resistant therapy isolates grew more slowly than pre-or posttherapy isolates did. There was, however, no correlation between reversion stability and a slow in vitro growth rate. This pattern of a return to quinolone susceptibility after the appearance of resistance has been documented previously (6, 7) .
In gram-negative bacteria, persistence mechanisms include modification of routes of drug entry and changes in target susceptibility. Both of these mechanisms have been shown to be involved in quinolone resistance in P. aeruginosa. In vitro-selected, quinolone-resistant mutants can occur by mutation of the DNA gyrase subunit A gene gyrA (nalA cfxA nfxA) (20, 36, 38 (36, 38) . For the recently described nfxC mutant (13) (30) or indirectly (6, 25) , and to outer membrane proteins (6, 7, 25, 35) and LPS (6, 30) . Most of these isolates do not fit the phenotypic patterns of in vitro-generated mutants of P. aeruginosa PAO or in vitrogenerated mutants of P. aeruginosa clinical isolates (28) . Recent work has shown that in vitro, the drug used for selection of mutants makes a large difference to the relative numbers of different resistance phenotypes (48) . However, this does not fully explain the phenotypic variations seen in clinical isolates, because at least five different phenotypes have been described in isolates from patients receiving ciprofloxacin in previously published reports (6, 7, 25, 30, 35) . The (22) .
Our investigations into the mechanisms of resistance implicated altered DNA gyrase and altered membrane permeability. Complementation studies with a susceptible gyrA gene probe showed increased susceptibility of transformants or transconjugants of sets P, U, and W. Complementation was, however, incomplete in sets U and W, indicating that alterations to DNA gyrase do not fully account for the ciprofloxacin resistance in these strains.
Changes in outer membrane proteins and LPS were also unique for the four strains examined. Protein bands appeared to be increased or decreased and were not confined to a particular size range. That these band changes had some connection with antimicrobial agent susceptibility changes was shown by the reversion of posttherapy banding patterns to those of the pretherapy isolates. Similarly, the changes in LPS of two therapy isolates reverted to the pretherapy pattern. Several protein bands in the region of 38 to 48 kDa appeared to be increased in ciprofloxacin-resistant isolates of sets P, U, and W. Assigning a function to a particular protein of a wild-type strain is difficult on the basis of molecular weight comparisons alone; however, these proteins are in the size region containing proteins OprE (OmpE), OprD (OmpD2), and OprB (OmpD1) (17) . These proteins have been proposed as outer membrane porins of P. aeruginosa (47, 49) . A monoclonal antibody (15) against OprF was used in an enzyme-linked immunosorbent assay of all therapy isolates (data not shown). The set Y therapy strain was confirmed to be the only OprF-strain. Previous studies have connected the loss of OprF with quinolone resistance (6, 35) ; however, susceptibility to nonquinolone antibiotics has been increased (this study), decreased (35) , or unaltered (6). Accumulation of [14C]ciprofloxacin was significantly decreased in the OprF-deficient set Y strain when compared with those in the pre-and posttherapy isolates, which expressed OprF.
Changes in susceptibility to P-lactams and chloramphenicol were found not to be related to antibiotic-modifying enzymes except in set P. The low-level ciprofloxacin-resistant therapy strain was found to have greatly increased expression of P-lactamase, causing high-level resistance to all ,-lactams tested with the exception of the P-lactamasestable carbapenem imipenem. The mechanism of this increased expression is under investigation. It should be stressed that the patient from whom this isolate was obtained was known not to have received therapy with a P-lactam antibiotic throughout the study period.
In summary, ciprofloxacin persistence in P. aeruginosa has been shown to be highly pleiotropic in terms of accompanying changes in susceptibility to nonquinolone antibiotics and changes to outer membrane proteins and LPS. It is known that changes in DNA gyrase activity or structure can alter expression of apparently unlinked genes (10) . It is possible that mutational changes in DNA gyrase genes that cause quinolone resistance affect the expression of other antibiotic resistance genes, such as those responsible for structure or control of expression of the outer membrane structure or P-lactamase. Alternatively, induction of the error-prone SOS DNA repair response by ciprofloxacin may cause multiple mutations in these genes.
